267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window

• Shahram Salek-Ardakani,
• Wenjing Yang,
• Sheng Ding,
• Shih-Hsun Chen,
• Jessica Stanfield,
• Nadia Kurd,
• Ryan Llewellyn,
• Jonathan Heyen,
• Carole Wang,
• Zea Melton,
• Javier Chaparro-Riggers,
• Pawel Dominik,
• Kevin Lindquist,
• Thomas Van Blarcom

Affiliations

Shahram Salek-Ardakani

Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Wenjing Yang

Computational Biology, Pfizer Inc, San Diego, California, USA

Sheng Ding

BioMedicine Design, Pfizer Inc, San Diego, California, USA

Shih-Hsun Chen

Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Jessica Stanfield

Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Nadia Kurd

Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Ryan Llewellyn

Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Jonathan Heyen

Drug Safety R&D, Pfizer Inc, San Diego, California, USA

Carole Wang

BioMedicine Design, Pfizer Inc, San Diego, California, USA

Zea Melton

BioMedicine Design, Pfizer Inc, San Diego, California, USA

Javier Chaparro-Riggers

BioMedicine Design, Pfizer Inc, San Diego, California, USA

Pawel Dominik

Pfizer, San Diego, CA, USA

Kevin Lindquist

Pfizer, San Diego, CA, USA

Thomas Van Blarcom

Pfizer, San Diego, CA, USA